Barry E. Greene - 04 Aug 2023 Form 4 Insider Report for Sage Therapeutics, Inc. (SAGE)

Role
President and CEO, Director
Signature
/s/ Jennifer Fitzpatrick, as Attorney-in-Fact for Barry Greene
Issuer symbol
SAGE
Transactions as of
04 Aug 2023
Net transactions value
$0
Form type
4
Filing time
08 Aug 2023, 16:15:55 UTC
Previous filing
25 May 2023
Next filing
15 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SAGE Stock Option (Right to Buy) Award $0 +195,000 $0.000000 195,000 04 Aug 2023 Common Stock 195,000 $85.82 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 4, 2021, the reporting person was granted an option to purchase 650,000 shares of common stock. The option vests upon the achievement of certain milestones, one of which was met on August 4, 2023, resulting in the vesting of the option as to 195,000 shares.